Price (delayed)
$325.06
Market cap
$10.1B
P/E Ratio
27.48
Dividend/share
N/A
EPS
$11.83
Enterprise value
$9.57B
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate
There are no recent dividends present for MEDP.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.